# Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

> **NCT02337205** · PHASE1 · COMPLETED · sponsor: **Athenex, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** KX2-391 Ointment

## Key facts

- **NCT ID:** NCT02337205
- **Lead sponsor:** Athenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2018-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337205, "Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02337205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*